前期原发性瘤切除与转移性结直肠癌的前期系统疗法:系统性审查和元分析
Shih-Jung Lo1, Shu-Huan Huang2, I-Li Lai2
1Department of Surgery, Chang Gung Memorial Hospital, Linkou, No.5, Fu-Hsing Street, Guei-Shan, Tao-Yuan, Taiwan.
International journal of colorectal disease
|July 5, 2023
概括
对转移性结直肠癌 (mCRC) 的前期原发性瘤切除 (PTR) 在随机试验中没有改善存活率,但增加了短期死亡率. 观察性研究表明潜在的生存益处,需要进一步研究.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 对转移性结直肠癌 (mCRC) 的最佳初始治疗策略进行了辩论.
- 这项研究比较了mCRC患者的前期初级瘤切除 (PTR) 与前期全身治疗 (ST).
结论:
- 对mCRC的前期PTR不会在RCT中增强OS,并增加短期死亡风险.
- 观察数据表明,前期PTR具有潜在的OS益处,但结果是相互矛盾的.
- 需要进一步进行大规模的RCT,以澄清前期PTR在mCRC管理中的作用.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
306
04:22Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
472
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
